Send us a text

Dr. Adam Rogers, MD is Chief Executive Officer of NervGen Pharma Corp. ( https://nervgen.com/ ) a clinical-stage biotech company dedicated to developing innovative treatments to enable nervous system repair in the settings of traumatic injury and disease. NervGen’s lead drug candidate, NVG-291, is being evaluated in mid stage clinical trials in an initial target indication, spinal cord injury. NervGen has initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury.

Dr. Rogers is a board-certified ophthalmologist specializing in diseases and surgery of the retina and vitreous, and previously co-founded and served as CEO of Hemera Biosciences, a clinical stage gene therapy biotech company targeting dry age-related macular degeneration where he oversaw all aspects of the company until the Hemera assets were acquired in December 2020 by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson.

From 2001 to 2020 Dr. Rogers served as an Assistant Professor of Ophthalmology at the New England Eye Center of Tufts Medical Center (Boston, MA). 

Dr. Rogers has published 29 articles in peer reviewed journals and co-authored two textbooks and numerous chapters in major ophthalmic textbooks. Since 2007 he has served on the board of One Family Inc., an organization whose mission is to end homelessness in Massachusetts. He is a member of the Emory University Board of Trustees. 

Dr. Rogers has a MD from Emory College and Emory School of Medicine.

#SpinalCordInjury #SCI #IschemicStroke #AmyotrophicLateralSclerosis #ALS #NervGen #Rehabilitation #RegenerativeMedicine #RegenerativeBiology #ChondroitinSulfateProteoglycans #STEM #Innovation #Science #Technology #Research #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcast

Support the show